Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary

Cardiff Oncology

25/02/2022 24:38

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 17 cents per share.
    * Revenue rose 11.8% to $133.00 thousand from a year ago; 
analysts expected $42.50 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 23 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.5%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Cardiff Oncology Inc shares had fallen by 55.4% this
quarter.
    * The company reported a quarterly loss of $9.45 million.
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 25 at 12:38 a.m.
 ​All figures in US dollars unless otherwise stated